|
ATCC
human synovial sarcoma cell line sw982 ![]() Human Synovial Sarcoma Cell Line Sw982, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+synovial+sarcoma+cell+line+sw982/pmc11821884-344-0-43?v=ATCC Average 96 stars, based on 1 article reviews
human synovial sarcoma cell line sw982 - by Bioz Stars,
2026-08
96/100 stars
|
Buy from Supplier |
|
Procell Inc
sw982 human synovial sarcoma cell line ![]() Sw982 Human Synovial Sarcoma Cell Line, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+synovial+sarcoma+cell+line+sw982/pm41401854-50-1-10?v=Procell+Inc Average 86 stars, based on 1 article reviews
sw982 human synovial sarcoma cell line - by Bioz Stars,
2026-08
86/100 stars
|
Buy from Supplier |
|
China Center for Type Culture Collection
human synovial sarcoma cell line sw982 ![]() Human Synovial Sarcoma Cell Line Sw982, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+synovial+sarcoma+cell+line+sw982/pm39748060-228-0-42?v=China+Center+for+Type+Culture+Collection Average 90 stars, based on 1 article reviews
human synovial sarcoma cell line sw982 - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
ATCC
human synovial sarcoma sw982 cell lines ![]() Human Synovial Sarcoma Sw982 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+synovial+sarcoma+cell+line+sw982/pmc12448324-65-6-22?v=ATCC Average 96 stars, based on 1 article reviews
human synovial sarcoma sw982 cell lines - by Bioz Stars,
2026-08
96/100 stars
|
Buy from Supplier |
|
ATCC
sw982 human synovial sarcoma cell line ![]() Sw982 Human Synovial Sarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+synovial+sarcoma+cell+line+sw982/pmc07915578-113-1-10?v=ATCC Average 96 stars, based on 1 article reviews
sw982 human synovial sarcoma cell line - by Bioz Stars,
2026-08
96/100 stars
|
Buy from Supplier |
Journal: EMBO Molecular Medicine
Article Title: A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors
doi: 10.1038/s44321-024-00184-1
Figure Lengend Snippet: ( A , B ) Tcr-T1 cells were generated as mentioned in the methods. Schematic for TCR-T cell generation, purification, and in vitro expansion. ( A ) Representative flow cytometric images indicated the electroporation efficiency and purification of Tcr-T1 cells ( B ). ( C ) HLA-A*2402-positive MKN45-Luci cells were treated with Tcr-T1 cells, with or without Pep-4 pulsing. 24 h later, cell viability was tested via CCK-8 assay. ( D ) Human synovial sarcoma cell line SW982 was modified with stable expression of the HLA-A*2402 molecule to generate target cells (SW982/2402). Then these target cells, SW982 and SW982/2402, were transfected with vectors expressing SYT-SSX fusion mutated peptide containing/deleting Pep-4 sequence (SYT-SSX ΔPep4, SYT-SSX, SYT-SSX ΔPep4/2402, and SYT-SSX/2402). Target cells were incubated with Tcr-T1 cells at ratio 0:1, 0.2:1, 1:1, and 5:1 (T-cell/SW982). Cell viability was determined by using CCK-8. ( E ) SW982 cells overexpressing HLA-A*2402 and SYT-SSX fusion mutated peptide containing Pep-4 sequence (SYT-SSX/2402) were incubated with Tcr-T1 cells ( E : T = 1:1). Cell viability was determined by CCK-8. IFN-γ secretion was examined using a CBA assay ( n = 3 independent replication). ( F ) Cytotoxicity of Tcr-T1 against HLA-A*2402-positive MKN45 was determined as indicated ( n = 3 independent replication). ( G – I ) Treatment scheme ( G , up). SYT-SSX/2402 and SYT-SSX ΔPep4/2402 cells (1 × 10 7 cells/mouse) were injected subcutaneously in nude mice ( n = 6). When tumor volume reached to ~100 mm 3 , Tcr-T1 cells, and UTD T cells (5 × 10 6 cells/mouse) were intravenously injected. Mice were sacrificed at the endpoint. Representative photographs of tumor tissues isolated from each group of mice ( G , bottom). Tumor volumes of each group were recorded ( H ). The overall survival of each group was recorded. ( I ) Data are presented as mean ± SEM. Statistical significance was calculated using the Student’s t test ( C , E ), one-way ANOVA ( C ), two-way ANOVA ( D – F , H ), and Kaplan–Meier survival analysis ( I ). ns not significant, * P < 0.05; ** P < 0.01; *** P < 0.001. .
Article Snippet:
Techniques: Generated, Purification, In Vitro, Electroporation, CCK-8 Assay, Modification, Expressing, Transfection, Sequencing, Incubation, Injection, Isolation
Journal: EMBO Molecular Medicine
Article Title: A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors
doi: 10.1038/s44321-024-00184-1
Figure Lengend Snippet: Reagents and tools table
Article Snippet:
Techniques: Cell Culture, Recombinant, Bicinchoninic Acid Protein Assay, Software
Journal: Marine Drugs
Article Title: Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization
doi: 10.3390/md19020093
Figure Lengend Snippet: TP4 triggers cell death in synovial sarcoma cells. Dose-dependent cytotoxicity of TP4 in SW982 cells ( A , B ) and Aska-SS cells ( C ). Cells were incubated with various concentrations of TP4 for 5 h. Time-dependent cytotoxicity of TP4 in SW982 cells ( D , E ) and Aska-SS cells ( F ). Cells were treated with TP4 (20 μg/mL) for the indicated times. Cytotoxicity was determined by the MTS/PMS assay ( A , C , D , F ) and trypan blue exclusion assay ( B , E ). *: p < 0.05 (Compared to 0 min or 0 μg/mL). IC50 values were calculated with GraphPad Prism 8 using a non-linear regression fit (log(inhibitor) vs. normalized response—variable slope).
Article Snippet: The
Techniques: Incubation, Trypan Blue Exclusion Assay
Journal: Marine Drugs
Article Title: Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization
doi: 10.3390/md19020093
Figure Lengend Snippet: Necrotic cell death is induced by TP4 in synovial sarcoma cells. Cells were treated with TP4 (20 μg/mL) or staurosporine (1 μM) for 5 h and 24 h, respectively. Vehicle control was 0.5% DMSO. Necrotic cell death was determined by the propidium iodide incorporation assay ( A ). ( B ) Cells (SW982 and Aska-SS) were treated as described above. Cell lysates and culture supernatants were collected and immunoblotted with indicated antibodies. Band intensities were analyzed with ImageJ software. *: p < 0.05 (Compared to vehicle). Cells (SW982 and Aska-SS) were preincubated with GSK’872 (5 μM) ( C , E ), Necrostatin-1 (10 μM) ( D , F ), or Z-VAD-FMK (100 μM) ( G , H ) for 1 h, followed by TP4 (20 μg/mL) for additional 5 h. Cell viability was analyzed using the trypan blue exclusion assay. *: p < 0.05 (Vehicle vs. TP4; TP4 vs. TP4 + inhibitor). Vehicle control: appropriate amount of DMSO.
Article Snippet: The
Techniques: Control, Software, Trypan Blue Exclusion Assay
Journal: Marine Drugs
Article Title: Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization
doi: 10.3390/md19020093
Figure Lengend Snippet: TP4 triggers oxidative stress. Synovial sarcoma cells were treated with TP4 (20 μg/mL) for the indicated times, and intracellular ROS was evaluated by DCF-DA ( A , B , E , F ) and DHE ( C , D ) fluorescence using flow cytometry. *: p < 0.05 (compared to 0 min). SW982 ( G ) and AsKa-SS ( H ) cells were preincubated with TEMPO (150 μM) for 1 h, followed by TP4 (20 μg/mL) for additional 5 h. Cell viability was determined using the trypan exclusion assay. *: p < 0.05 (Vehicle vs. TP4; TP4 vs. TP4 + TEMPO). ( I ) SW982 cells were treated with TP4 (20 μg/mL) for the indicated times, and cell lysates were collected and immunoblotted with the indicated antibodies. UCP-2: uncoupling protein-2; GPx: glutathione peroxidase; SOD-1: superoxide dismutase-1; SOD-2: superoxide dismutase-2. ( J – N ) Band intensities were analyzed with ImageJ. *: p < 0.05 (Compared to 0 min).
Article Snippet: The
Techniques: Fluorescence, Flow Cytometry, Exclusion Assay
Journal: Marine Drugs
Article Title: Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization
doi: 10.3390/md19020093
Figure Lengend Snippet: TP4 induces mitochondrial hyperpolarization and mitochondrial ROS generation. SW982 ( A , B ) and AsKa-SS ( C , D ) cells were treated with TP4 (20 μg/mL) for 0, 15, 30, 60, 180 and 300 min. TMRE intensity was analyzed by flow cytometry. SW982 ( E , F ) and AsKa-SS ( G , H ) cells were treated with TP4 (20 μg/mL), as described in ( A – D ), followed by MitoSOX Red (5 μM) for an additional 15 min. MitoSOX Red fluorescence intensity was determined by flow cytometry. *: p < 0.05 (Compared to 0 min).
Article Snippet: The
Techniques: Flow Cytometry, Fluorescence
Journal: Marine Drugs
Article Title: Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization
doi: 10.3390/md19020093
Figure Lengend Snippet: TP4 triggers calcium overload. SW982 ( A , B ) and AsKa-SS ( C , D ) cells were preloaded with Fluo-4 (5 μM) for 15 min, followed by TP4 treatment. After 0, 15, 30, 60, 180 or 300 min, Fluo-4 intensity was analyzed by flow cytometry. *: p < 0.05 (compared to 0 min). SW982 ( E , F ) and Aska-SS ( G ) cells were preincubated with BAPTA (10 μM) for 1 h, followed by TP4 (20 μg/mL) for 5 h. Then, cells were incubated with DCF-DA for 15 min. DCF-DA intensity was analyzed by flow cytometry. *: p < 0.05 (Vehicle vs. TP4; TP4 vs. TP4 + BAPTA). SW982 ( H ) and AsKa-SS ( I ) cells were preincubated with BAPTA (10 μM) for 1 h, followed by TP4 (20 μg/mL) for an additional 5 h. Cell viability was determined using the trypan exclusion assay. *: p < 0.05 (Vehicle vs. TP4; TP4 vs. TP4 + BAPTA). SW982 ( J ) and AsKa-SS ( K , L ) cells were incubated with TP4 (20 μg/mL) for 300 min. TMRE intensity was analyzed by flow cytometry. *: p < 0.05 (Vehicle vs. TP4; TP4 vs. TP4 + BAPTA).
Article Snippet: The
Techniques: Flow Cytometry, Incubation, Exclusion Assay